The HIV drug market size attained a value of USD 33.54 Billion in 2024. The market is anticipated to grow at a CAGR of 4.50% during the forecast period of 2025-2034 to attain a value of USD 52.09 Billion by 2034.
HIV Drugs Market Overview
Human immunodeficiency virus (HIV) is a life-threatening condition that can be transferred from one person to another through blood and/or sexual contact. It damages the immune system by destroying CD-4 cells, making the body susceptible to infections and other diseases. The rising prevalence of HIV disease has positively impacted the demand for HIV drugs. According to the estimates by the World Health Organization (WHO), 39 million people are living with HIV. Approximately 0.7% of adults aged between 15-49 years are living with this condition worldwide. The growing population density of HIV-infected people has been instrumental in the development and introduction of HIV drugs.
The HIV drugs market growth is influenced by the rising government initiatives and campaigns to create awareness amongst people regarding the causes, symptoms, and treatments of the condition. At present, highly active antiretroviral therapy (HAART) is the most prescribed treatment. It has various combinations of one protease inhibitor and other drugs. These combinations aid in increasing the number of CD4+ cells and decreasing the amount of virus in the blood. The introduction of generic drug acts is another factor that is contributing to the demand for HIV drugs, as they are cost-effective and chemically identical to branded drugs. The market is experiencing increased advancement in the treatment technologies by the market players. Such advancements are significantly expected to drive the market growth.
Expedited Drug Development to Boost HIV Drugs Market Share
In October 2023, Gilead Sciences, Inc. revealed that Sunlenca® (lenacapavir), their latest drug was well supported to treat multi-drug resistant (MDR) HIV in adults. Administered twice a year, Sunlenca is a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor, used in combination with other antiretrovirals. The drug is expected to be made available in oral as well as injectable mode of administration along with multiple dosage forms. The increasing advancements to bring customization and offer precise treatment to patients is poised to drive the market for HIV drugs in the forecast period.
Surge in Clinical Trials to Meet the Rising HIV Drugs Market Demand
The market growth is poised to be driven by the rising number of clinical trials and continued efforts by researchers to discover an effective treatment novel therapy to treat HIV. For instance, in April 2023, UC Davis Health researchers deployed CAR T cell therapy to treat patients suffering from HIV . Leveraging immunotherapy, the first patient was dosed with anti-HIV duoCAR T cells to stimulate the immune system and treat the condition. The clinical trial was designed for 9 candidates, divided in 3 cohorts wherein patients from each cohort underwent different treatment combinations. This is indicative of rising application of advanced and alternative therapies to treat the fatal disease.
HIV Drugs Market Segmentation
Market Breakup by Medication Class:
- Multi-Class Combination Drugs
- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- Protease Inhibitors (Pls)
- Entry Inhibitors
- HIV Integrase Strand Transfer Inhibitors
- Others
- Hospitals Pharmacies
- Drug stores and Retail Pharmacies
- Online Pharmacies
- Hospitals
- Clinics
- Others
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- China
Geographically, North America is expected to lead the market share in the forecast period. The regional growth can be attributed to a well-established healthcare system, and the growing adoption of advanced treatment options for the HIV-infected population. The HIV drugs market size is significantly impacted by the increased number of research and development initiatives for new drug launches.
In September 2023, researchers at Johns Hopkins found a new injectable solution that could help manage HIV, unlike any currently available methods in the market. This new solution self-assembles into a gel under the right conditions. It releases a steady dose of the anti-HIV drug lamivudine over six weeks. The major issue that patients face while following an HIV treatment regimen is the daily management of the doses. However, this new gel treatment is poised to help people living with HIV to have a new therapy that doesn't require a daily pill regimen to prevent AIDS, making it less stressful and easy to follow.
The Asia Pacific region is also poised to experience significant HIV drugs market growth, owing to increasing infrastructure improvements and emphasis on spreading awareness about the condition amongst marginalised communities.
HIV Drugs Market: Competitor Landscape
In February 2022, ViiV Healthcare , the global specialist HIV company, announced the US Food and Drug Administration (FDA) approval for Cabenuva (cabotegravir, rilpivirine) for every two months dosing for the treatment of HIV-1 in virologically suppressed adults. The drug constitutes an extended-release injectable suspension in a single vial dose, making it suitable for easy administration. The approval was based on the positive results from ATLAS-2M phase IIIb trial.
The key features of the HIV drugs market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- ViiV Healthcare Group of Companies
- Gilead Sciences, Inc.
- GSK Plc.
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- Johnson & Johnson Services, Inc.
- Boehringer Ingelheim International GmbH
- AbbVie Inc.
- Genentech, Inc.
- Mylan N.V.
- CytoDyn Inc.
- Daichii Sankyo Company, Limited
- Pfizer Inc.
- Shantou Huatai Pharmaceutical Co., Ltd.
- Shengzhen Chongway Biotechnology Co., Ltd
More Insights On
United States HIV Drugs Market
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 HIV Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 HIV Epidemiology Analysis – 8 Major Markets
- 5.1 8MM Epidemiology Scenario Overview (2018-2034)
- 5.2 United States HIV Epidemiology Forecast (2018-2034)
- 5.3 EU-4 and United Kingdom HIV Epidemiology Forecast (2018-2034)
- 5.3.1 Germany HIV Epidemiology Forecast (2018-2034)
- 5.3.2 France HIV Epidemiology Forecast (2018-2034)
- 5.3.3 Italy HIV Epidemiology Forecast (2018-2034)
- 5.3.4 Spain HIV Epidemiology Forecast (2018-2034)
- 5.3.5 United Kingdom HIV Epidemiology Forecast (2018-2034)
- 5.4 Japan HIV Epidemiology Forecast (2018-2034)
- 6 HIV Drugs Market Overview – 8 Major Markets
- 6.1 HIV Drugs Market Historical Value (2018-2024)
- 6.2 HIV Drugs Market Forecast Value (2025-2034)
- 7 HIV Drugs Market Landscape – 8 Major Markets
- 7.1 HIV Drugs: Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 HIV Drugs: Product Landscape
- 7.2.1 Analysis by Type
- 7.2.2 Analysis by Medication Class
- 8 HIV Drugs Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 HIV Drugs Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 HIV Drugs Market Segmentation-8 Major Markets
- 11.1 HIV Drugs Market by Medication Class
- 11.1.1 Market Overview
- 11.1.2 Multi-Class Combination Drugs
- 11.1.3 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- 11.1.4 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- 11.1.5 Protease Inhibitors (PIs)
- 11.1.6 Entry Inhibitors
- 11.1.7 HIV Integrase Strand Transfer Inhibitors
- 11.1.8 Others
- 11.2 HIV Drugs Market by Distribution Channel
- 11.2.1 Market Overview
- 11.2.2 Hospital Pharmacies
- 11.2.3 Drugs stores and retail pharmacies
- 11.2.4 Online pharmacies
- 11.3 HIV Drugs Market by End User
- 11.3.1 Market Overview
- 11.3.2 Hospitals
- 11.3.3 Clinics
- 11.3.4 Others
- 11.4 HIV Drugs Market by Region
- 11.4.1 Market Overview
- 11.4.2 United States
- 11.4.3 EU-4 and the United Kingdom
- 11.4.3.1 Germany
- 11.4.3.2 France
- 11.4.3.3 Italy
- 11.4.3.4 Spain
- 11.4.3.5 United Kingdom
- 11.4.4 Japan
- 11.4.5 China
- 12 United States HIV Drugs Market
- 12.1 HIV Drugs Market Historical Value (2018-2024)
- 12.2 HIV Drugs Market Forecast Value (2025-2034)
- 12.3 United States HIV Drugs Market by Medication Class
- 12.3.1 Market Overview
- 12.3.2 Multi-Class Combination Drugs
- 12.3.3 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- 12.3.4 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- 12.3.5 Protease Inhibitors (PIs)
- 12.3.6 Entry Inhibitors
- 12.3.7 HIV Integrase Strand Transfer Inhibitors
- 12.3.8 Others
- 12.4 United States HIV Drugs Market by Distribution Channel
- 12.4.1 Market Overview
- 12.4.2 Hospital Pharmacies
- 12.4.3 Drugs stores and retail pharmacies
- 12.4.4 Online pharmacies
- 13 EU-4 and United Kingdom HIV Drugs Market
- 13.1 EU-4 and United Kingdom HIV Drugs Market Historical Value (2018-2024)
- 13.2 EU-4 and United Kingdom HIV Drugs Market Forecast Value (2025-2034)
- 13.3 EU-4 and United Kingdom HIV Drugs Market Overview
- 13.4 EU-4 and United Kingdom HIV Drugs Market by Medication Class
- 13.4.1 Market Overview
- 13.4.2 Multi-Class Combination Drugs
- 13.4.3 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- 13.4.4 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- 13.4.5 Protease Inhibitors (PIs)
- 13.4.6 Entry Inhibitors
- 13.4.7 HIV Integrase Strand Transfer Inhibitors
- 13.4.8 Others
- 13.5 EU-4 and United Kingdom HIV Drugs Market by Distribution Channel
- 13.5.1 Market Overview
- 13.5.2 Hospital Pharmacies
- 13.5.3 Drugs stores and retail pharmacies
- 13.5.4 Online pharmacies
- 14 Japan HIV Drugs Market
- 14.1 Japan HIV Drugs Market Historical Value (2018-2024)
- 14.2 Japan HIV Drugs Market Forecast Value (2025-2034)
- 14.3 Japan HIV Drugs Market by Medication Class
- 14.3.1 Market Overview
- 14.3.2 Multi-Class Combination Drugs
- 14.3.3 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- 14.3.4 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- 14.3.5 Protease Inhibitors (PIs)
- 14.3.6 Entry Inhibitors
- 14.3.7 HIV Integrase Strand Transfer Inhibitors
- 14.3.8 Others
- 14.4 Japan HIV Drugs Market by Distribution Channel
- 14.4.1 Market Overview
- 14.4.2 Hospital Pharmacies
- 14.4.3 Drugs stores and retail pharmacies
- 14.4.4 Online pharmacies
- 15 China HIV Drugs Market
- 15.1 China HIV Drugs Market Historical Value (2018-2024)
- 15.2 China HIV Drugs Market Forecast Value (2025-2034)
- 15.3 China HIV Drugs Market by Medication Class
- 15.3.1 Market Overview
- 15.3.2 Multi-Class Combination Drugs
- 15.3.3 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- 15.3.4 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- 15.3.5 Protease Inhibitors (PIs)
- 15.3.6 Entry Inhibitors
- 15.3.7 HIV Integrase Strand Transfer Inhibitors
- 15.3.8 Others
- 15.4 China HIV Drugs Market by Distribution Channel
- 15.4.1 Market Overview
- 15.4.2 Hospital Pharmacies
- 15.4.3 Drugs stores and retail pharmacies
- 15.4.4 Online pharmacies
- 16 Regulatory Framework
- 16.1 Regulatory Overview
- 16.1.1 US FDA
- 16.1.2 EU EMA
- 16.1.3 INDIA CDSCO
- 16.1.4 JAPAN PMDA
- 16.1.5 Others
- 17 Patent Analysis
- 17.1 Analysis by Type of Patent
- 17.2 Analysis by Publication Year
- 17.3 Analysis by Issuing Authority
- 17.4 Analysis by Patent Age
- 17.5 Analysis by CPC Analysis
- 17.6 Analysis by Patent Valuation
- 17.7 Analysis by Key Players
- 18 Grants Analysis
- 18.1 Analysis by Year
- 18.2 Analysis by Amount Awarded
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Grant Application
- 18.5 Analysis by Funding Institute
- 18.6 Analysis by NIH Departments
- 18.7 Analysis by Recipient Organization
- 19 Clinical Trials Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Funding and Investment Analysis
- 20.1 Analysis by Funding Instances
- 20.2 Analysis by Type of Funding
- 20.3 Analysis by Funding Amount
- 20.4 Analysis by Leading Players
- 20.5 Analysis by Leading Investors
- 20.6 Analysis by Geography
- 21 Partnership and Collaborations Analysis
- 21.1 Analysis by Partnership Instances
- 21.2 Analysis by Type of Partnership
- 21.3 Analysis by Leading Players
- 21.4 Analysis by Geography
- 22 Supplier Landscape
- 22.1 ViiV Healthcare Group of Companies
- 22.1.1 Financial Analysis
- 22.1.2 Product Portfolio
- 22.1.3 Demographic Reach and Achievements
- 22.1.4 Mergers and Acquisitions
- 22.1.5 Certifications
- 22.2 Gilead Sciences, Inc.
- 22.2.1 Financial Analysis
- 22.2.2 Product Portfolio
- 22.2.3 Demographic Reach and Achievements
- 22.2.4 Mergers and Acquisitions
- 22.2.5 Certifications
- 22.3 GSK Plc.
- 22.3.1 Financial Analysis
- 22.3.2 Product Portfolio
- 22.3.3 Demographic Reach and Achievements
- 22.3.4 Mergers and Acquisitions
- 22.3.5 Certifications
- 22.4 Merck & Co., Inc.
- 22.4.1 Financial Analysis
- 22.4.2 Product Portfolio
- 22.4.3 Demographic Reach and Achievements
- 22.4.4 Mergers and Acquisitions
- 22.4.5 Certifications
- 22.5 Bristol-Myers Squibb Company
- 22.5.1 Financial Analysis
- 22.5.2 Product Portfolio
- 22.5.3 Demographic Reach and Achievements
- 22.5.4 Mergers and Acquisitions
- 22.5.5 Certifications
- 22.6 Johnson & Johnson Services, Inc.
- 22.6.1 Financial Analysis
- 22.6.2 Product Portfolio
- 22.6.3 Demographic Reach and Achievements
- 22.6.4 Mergers and Acquisitions
- 22.6.5 Certifications
- 22.7 Boehringer Ingelheim International GmbH
- 22.7.1 Financial Analysis
- 22.7.2 Product Portfolio
- 22.7.3 Demographic Reach and Achievements
- 22.7.4 Mergers and Acquisitions
- 22.7.5 Certifications
- 22.8 AbbVie Inc.
- 22.8.1 Financial Analysis
- 22.8.2 Product Portfolio
- 22.8.3 Demographic Reach and Achievements
- 22.8.4 Mergers and Acquisitions
- 22.8.5 Certifications
- 22.9 Genentech, Inc.
- 22.9.1 Financial Analysis
- 22.9.2 Product Portfolio
- 22.9.3 Demographic Reach and Achievements
- 22.9.4 Mergers and Acquisitions
- 22.9.5 Certifications
- 22.10 Mylan N.V.
- 22.10.1 Financial Analysis
- 22.10.2 Product Portfolio
- 22.10.3 Demographic Reach and Achievements
- 22.10.4 Mergers and Acquisitions
- 22.10.5 Certifications
- 22.11 CytoDyn Inc.
- 22.11.1 Financial Analysis
- 22.11.2 Product Portfolio
- 22.11.3 Demographic Reach and Achievements
- 22.11.4 Mergers and Acquisitions
- 22.11.5 Certifications
- 22.12 Daichii Sankyo Company, Limited
- 22.12.1 Financial Analysis
- 22.12.2 Product Portfolio
- 22.12.3 Demographic Reach and Achievements
- 22.12.4 Mergers and Acquisitions
- 22.12.5 Certifications
- 22.13 Pfizer Inc.
- 22.13.1 Financial Analysis
- 22.13.2 Product Portfolio
- 22.13.3 Demographic Reach and Achievements
- 22.13.4 Mergers and Acquisitions
- 22.13.5 Certifications
- 22.14 Shantou Huatai Pharmaceutical Co., Ltd.
- 22.14.1 Financial Analysis
- 22.14.2 Product Portfolio
- 22.14.3 Demographic Reach and Achievements
- 22.14.4 Mergers and Acquisitions
- 22.14.5 Certifications
- 22.15 Shengzhen Chongway Biotechnology Co., Ltd
- 22.15.1 Financial Analysis
- 22.15.2 Product Portfolio
- 22.15.3 Demographic Reach and Achievements
- 22.15.4 Mergers and Acquisitions
- 22.15.5 Certifications
- 23 HIV Drugs - Distribution Model (Additional Insight)
- 23.1 Overview
- 23.2 Potential Distributors
- 23.3 Key Parameters for Distribution Partner Assessment
- 24 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 25 Company Competitiveness Analysis (Additional Insight)
- 25.1 Very Small Companies
- 25.2 Small Companies
- 25.3 Mid-Sized Companies
- 25.4 Large Companies
- 25.5 Very Large Companies
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook